Literature DB >> 8901844

The role of genetic polymorphisms of angiotensin-converting enzyme in the progression of renal diseases.

K J McLaughlin1, P N Harden, S Ueda, J M Boulton-Jones, J M Connell, A G Jardine.   

Abstract

The renin-angiotensin system is likely to be important in the progression of renal diseases because of its effect on tissue hemodynamics and glomerular cell function. Recent evidence from small studies has suggested a possible role for the genetic determinants of angiotensin converting enzyme activity in the rate of progression of renal failure. We studied the effect of the insertion/deletion (I/D) polymorphism of the angiotensin-converting enzyme gene on the rate of renal function deterioration in 822 patients with a variety of renal diseases. We found that the slope of the reciprocal serum creatinine-versus-time plot was steeper in patients homozygous for the deletion allele (DD) compared with those homozygous for the insertion allele (II) (P = .015). When patients with similar renal function at presentation (creatinine < 200 mumol/L) were compared, II homozygotes had significantly improved renal survival (P = .039). Separate analyses of patients with glomerular diseases and tubulointerstitial diseases demonstrated an effect of this genotype in glomerular diseases only. These data provide further evidence of the possible role of the angiotensin-converting enzyme gene in the rate of progression of renal failure, although further studies are required to evaluate the role of this and other proposed candidate genes in renal diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8901844     DOI: 10.1161/01.hyp.28.5.912

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  8 in total

1.  Association of TNF-α -308 G > A and ACE I/D gene polymorphisms in hemodialysis patients with arteriovenous fistula thrombosis.

Authors:  Elif Funda Sener; Serpil Taheri; Keziban Korkmaz; Gokmen Zararsiz; Faruk Serhatlioglu; Aydin Unal; Omer Naci Emirogullari; Yusuf Ozkul
Journal:  Int Urol Nephrol       Date:  2013-10-15       Impact factor: 2.370

Review 2.  Should we aim at tissue renin-angiotensin systems?

Authors:  J F Smits; R C Passier; M J Daemen
Journal:  Pharm World Sci       Date:  1998-06

3.  Association of angiotensin-converting enzyme and endothelial Nitric Oxide synthase gene polymorphisms with vascular disease in ESRD patients in a Chinese population.

Authors:  Feng-Ying Tang; Fu-You Liu; Xiong-Wei Xie
Journal:  Mol Cell Biochem       Date:  2008-07-16       Impact factor: 3.396

4.  Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention.

Authors:  A Titia Lely; Frank G H van der Kleij; Taco J Kistemaker; Alfred J Apperloo; Paul E de Jong; Dick de Zeeuw; Gerjan Navis
Journal:  Clin J Am Soc Nephrol       Date:  2007-12-12       Impact factor: 8.237

5.  High prevalence of ACE DD genotype among north Indian end stage renal disease patients.

Authors:  Gaurav Tripathi; Poonam Dharmani; Faisal Khan; R K Sharma; Vinod Pandirikkal; Suraksha Agrawal
Journal:  BMC Nephrol       Date:  2006-10-17       Impact factor: 2.388

6.  Quality of life as an outcome in Alzheimer's disease and other dementias--obstacles and goals.

Authors:  Matthias W Riepe; Thomas Mittendorf; Hans Förstl; Lutz Frölich; Martin Haupt; Reiner Leidl; Christoph Vauth; Matthias Graf von der Schulenburg
Journal:  BMC Neurol       Date:  2009-08-25       Impact factor: 2.474

Review 7.  Cardiovascular disease in patients with chronic kidney disease.

Authors:  Julian Wright; Alastair Hutchison
Journal:  Vasc Health Risk Manag       Date:  2009-09-07

Review 8.  Angiotensin-converting enzyme insertion/deletion polymorphism contributes high risk for chronic kidney disease in Asian male with hypertension--a meta-regression analysis of 98 observational studies.

Authors:  Chin Lin; Hsin-Yi Yang; Chia-Chao Wu; Herng-Sheng Lee; Yuh-Feng Lin; Kuo-Cheng Lu; Chi-Ming Chu; Fu-Huang Lin; Sen-Yeong Kao; Sui-Lung Su
Journal:  PLoS One       Date:  2014-01-31       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.